Market
Immunocore announces new KIMMTRAK trial for different cancer type by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Immunocore or clinical trial registries
Story
NHS Offers KIMMTRAK to HLA-A*02:01-Positive Adults with Previously Untreatable Uveal Melanoma
Dec 3, 2024, 07:10 AM
A significant advancement in cancer treatment has been announced in England, with hundreds of patients diagnosed with unresectable or metastatic uveal melanoma set to receive access to KIMMTRAK, a pioneering drug developed by Immunocore. The National Health Service (NHS) confirmed that this reimbursement agreement will allow HLA-A*02:01-positive adults to access the treatment, which is expected to extend their lives by several months. This breakthrough, described as a 'game changer,' was developed by a research team in Oxford and marks a major milestone for patients suffering from this rare and previously untreatable form of eye cancer.
View original story
Similar markets
Colorectal cancer • 25%
Other • 25%
Lung cancer • 25%
Breast cancer • 25%
Successful with no major issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trials delayed • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Oracle • 25%
Pfizer • 25%
Moderna • 25%
Other • 25%
